Pazopanib

Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
Votrient, GW786034B, GSK-VEG10003
API & Intermediates
KAPI0F21
444731-52-6
MFCD11616589
10113978

image-155171-Trimethyl(trifluoromethyl)silane_reagent.png
Chemical Name
Molecular Formula
Molecular Weight
Assay
Appearance
Melting Point
Packaging
Storage
Pazopanib
C21H23N7O2S
437.52
≥99%(HPLC)
White to Off-white Solid
>255°C
500mg,1g,2g,5g,10g,25g,50g,100g and 500g
-20°C Freezer
Pazopanib (also known as Votrient, GW786034B, GSK-VEG10003) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which blocks tumour growth and inhibits angiogenesis. It is typically used to treat renal cell carcinoma and soft tissue sarcoma.
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. [1]
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). [2]
Comprehensive analysis of kinase inhibitor selectivity. [3]
Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. [4]
Concise Drug Review: Pazopanib and Axitinib. [5]
Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. [6]
Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence. [7]
References:
[1] K.Podar, et al, Proc. Natl. Acad. Sci. USA, 2006, 103(51), pp 19478-19483.
[2] S.Sleijfer, et al, J. Clin. Oncol., 2009, 27(19), pp 3126-3132.
[3] M.I.Davis, et al, Nat. Biotechnol., 2011, 29(11), pp 1046-1051.
[4] S.V.Ulahannan, et al, Cancer Invest.,  2011, 29(4), pp 325-337.
[5] R.M.J.M.van Geel, et al, Oncologist, 2012, 17(8), pp 1081-1089.
[6] J.C.Uitdehaag, et al, PLoS One, 2014, 9(3), pp e92146:1-13.
[7] M.Sun, et al, Int. Nephrol. Renovasc. Dis., 2014, 7, pp 401-407.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Warning
P302,P315,P319,P335
P261,P264,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P312

NONH for all modes of transport
Sales restrictions may apply.
1. Product Specification
2. Safety Data Sheet
Available on request.
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.